Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
104 hedge funds and large institutions have $80.8M invested in Sanofi Contingent Value Rights in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 9 closing their positions.
18% more capital invested
Capital invested by funds: $68.8M → $80.8M (+$12.1M)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 105 → 104 (-1)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$2.08M |
| 2 |
BHMP
Bardin Hill Management Partners
New York
|
+$1.12M |
| 3 |
NGA
New Generation Advisors
Manchester,
Massachusetts
|
+$844K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$580K |
| 5 |
BMO
Beck Mack & Oliver
New York
|
+$147K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$2.89M |
| 2 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$499K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$56.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$43.6K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$25.2K |
GCVRZ Hedge Fund Activity: Q2 2019 in Review
104 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2019, worth a combined $80.8M — up 18% from $68.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GCVRZ positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 18 trimmed.
The largest buyer was Stonehill Capital Management, adding an estimated $2.08M. The largest seller was Highbridge Capital Management, cutting an estimated $2.89M.
- 104 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2019, down from 105 in Q1 2019.
- Funds reported $80.8M of Sanofi Contingent Value Rights stock for Q2 2019, up 18% quarter-over-quarter.
- 10 funds opened new Sanofi Contingent Value Rights positions in Q2 2019 and 9 closed out, a net change of +1 holder.
- The largest Sanofi Contingent Value Rights buyer in Q2 2019 was Stonehill Capital Management, an estimated $2.08M added.
- The largest Sanofi Contingent Value Rights seller in Q2 2019 was Highbridge Capital Management, an estimated $2.89M sold.
Based on aggregated 13F filings for Q2 2019.